The global human recombinant insulin market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of diabetes and obesity in developing countries, which are driving the demand for insulin products. Insulin is an important component in diabetes management as it helps regulate blood sugar levels by lowering glucose levels in the blood. It also helps maintain healthy weight by reducing appetite and controlling hunger pangs. Insulin products are classified into four types: RapiActing Human Insulin, Regular (Short Acting) Insulin, NPH (Intermediate Acting) Insulin, LonActing Human Insulin and Premixed Human Insulins. The RapiActing Human Insulin segment accounted for a significant share of the global human recombinant insulin market in 2017 owing to its ability to provide rapid onset action with short duration of action that can be used before or after meals or before bedtime as per requirement. Regular (Short Acting) Insulin accounted for a significant share with respect to revenue due to its long-acting effect that lasts up until 12 hours after administration and can be taken once or twice daily depending on requirements; it also has low risk of hypoglycemia when compared with other types such as NPH (Intermediate Acting) and LonActing Human insulins which have longer duration but higher risk of hypoglycemia respectively due their prolonged action time periods that last up until 18 hours after administration time period.
Some Of The Growth Factors Of This Market:
- Insulin is used to treat diabetes mellitus type 1 and type 2, which are both chronic diseases that affect millions of people worldwide.
- The global population is aging, which will lead to an increase in the number of people with diabetes mellitus type 2 and other chronic diseases that require insulin treatment. This will drive demand for human recombinant insulin over the next few years as well as increase competition among manufacturers in this market segment.
Industry Growth Insights published a new data on “Human Recombinant Insulin Market”. The research report is titled “Human Recombinant Insulin Market research by Types (Rapid-Acting Human Insulin, Regular (Short Acting) Insulin, NPH (Intermediate Acting) Insulin, Long-Acting Human Insulin, Premixed Human Insulins Insulin), By Applications (Hospital, Retail Pharmacy, Online Pharmacies, Other), By Players/Companies Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, PeproTech”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Recombinant Insulin Market Research Report
By Type
Rapid-Acting Human Insulin, Regular (Short Acting) Insulin, NPH (Intermediate Acting) Insulin, Long-Acting Human Insulin, Premixed Human Insulins Insulin
By Application
Hospital, Retail Pharmacy, Online Pharmacies, Other
By Companies
Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, PeproTech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Human Recombinant Insulin Market Report Segments:
The global Human Recombinant Insulin market is segmented on the basis of:
Types
Rapid-Acting Human Insulin, Regular (Short Acting) Insulin, NPH (Intermediate Acting) Insulin, Long-Acting Human Insulin, Premixed Human Insulins Insulin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy, Online Pharmacies, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- Julphar Gulf Pharmaceutical Industries
- Bioton
- Gan & Lee Pharmaceuticals
- Zhuhai United Laboratories
- Biocon
- Wanbang Biopharmaceuticals
- Dongbao Enterprise Group
- PeproTech
Highlights of The Human Recombinant Insulin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rapid-Acting Human Insulin
- Regular (Short Acting) Insulin
- NPH (Intermediate Acting) Insulin
- Long-Acting Human Insulin
- Premixed Human Insulins Insulin
- By Application:
- Hospital
- Retail Pharmacy
- Online Pharmacies
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Recombinant Insulin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human recombinant insulin is a type of insulin that has been created in a laboratory. It is made from human cells and can be more accurate than regular insulin because it has been specifically designed to match the body's own natural production of insulin. This means that human recombinant insulin may be less likely to cause side effects, such as weight gain or diabetes complications.
Some of the key players operating in the human recombinant insulin market are Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, PeproTech.
The human recombinant insulin market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Recombinant Insulin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Recombinant Insulin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Recombinant Insulin Market - Supply Chain
4.5. Global Human Recombinant Insulin Market Forecast
4.5.1. Human Recombinant Insulin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Recombinant Insulin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Human Recombinant Insulin Market Absolute $ Opportunity
5. Global Human Recombinant Insulin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Human Recombinant Insulin Market Size and Volume Forecast by Type
5.3.1. Rapid-Acting Human Insulin
5.3.2. Regular (Short Acting) Insulin
5.3.3. NPH (Intermediate Acting) Insulin
5.3.4. Long-Acting Human Insulin
5.3.5. Premixed Human Insulins Insulin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Human Recombinant Insulin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Human Recombinant Insulin Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacies
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Human Recombinant Insulin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Human Recombinant Insulin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Human Recombinant Insulin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Recombinant Insulin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Recombinant Insulin Demand Share Forecast, 2019-2026
9. North America Human Recombinant Insulin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Recombinant Insulin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Recombinant Insulin Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacies
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Human Recombinant Insulin Market Size and Volume Forecast by Type
9.7.1. Rapid-Acting Human Insulin
9.7.2. Regular (Short Acting) Insulin
9.7.3. NPH (Intermediate Acting) Insulin
9.7.4. Long-Acting Human Insulin
9.7.5. Premixed Human Insulins Insulin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Human Recombinant Insulin Demand Share Forecast, 2019-2026
10. Latin America Human Recombinant Insulin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Recombinant Insulin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Recombinant Insulin Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacies
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Human Recombinant Insulin Market Size and Volume Forecast by Type
10.7.1. Rapid-Acting Human Insulin
10.7.2. Regular (Short Acting) Insulin
10.7.3. NPH (Intermediate Acting) Insulin
10.7.4. Long-Acting Human Insulin
10.7.5. Premixed Human Insulins Insulin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Human Recombinant Insulin Demand Share Forecast, 2019-2026
11. Europe Human Recombinant Insulin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Recombinant Insulin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Recombinant Insulin Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacies
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Human Recombinant Insulin Market Size and Volume Forecast by Type
11.7.1. Rapid-Acting Human Insulin
11.7.2. Regular (Short Acting) Insulin
11.7.3. NPH (Intermediate Acting) Insulin
11.7.4. Long-Acting Human Insulin
11.7.5. Premixed Human Insulins Insulin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Human Recombinant Insulin Demand Share, 2019-2026
12. Asia Pacific Human Recombinant Insulin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Recombinant Insulin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Recombinant Insulin Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacies
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Human Recombinant Insulin Market Size and Volume Forecast by Type
12.7.1. Rapid-Acting Human Insulin
12.7.2. Regular (Short Acting) Insulin
12.7.3. NPH (Intermediate Acting) Insulin
12.7.4. Long-Acting Human Insulin
12.7.5. Premixed Human Insulins Insulin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Human Recombinant Insulin Demand Share, 2019-2026
13. Middle East & Africa Human Recombinant Insulin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Human Recombinant Insulin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Recombinant Insulin Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacies
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Human Recombinant Insulin Market Size and Volume Forecast by Type
13.7.1. Rapid-Acting Human Insulin
13.7.2. Regular (Short Acting) Insulin
13.7.3. NPH (Intermediate Acting) Insulin
13.7.4. Long-Acting Human Insulin
13.7.5. Premixed Human Insulins Insulin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Human Recombinant Insulin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Human Recombinant Insulin Market: Market Share Analysis
14.2. Human Recombinant Insulin Distributors and Customers
14.3. Human Recombinant Insulin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Eli Lilly and Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Julphar Gulf Pharmaceutical Industries
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bioton
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Gan & Lee Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zhuhai United Laboratories
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biocon
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Wanbang Biopharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Dongbao Enterprise Group
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. PeproTech
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook